Reviewed by the Peptica editorial team
Published 5 June 2026
Source-based, neutral information — no medical advice, no sales. Editorial standards
Retatrutide is one of the most-discussed metabolic peptides of recent years. The reason: it acts as a so-called triple agonist on three receptor systems at once. In early clinical trials this produced especially large average weight reductions. Important up front: retatrutide is still in clinical testing and not approved. This article neutrally summarizes what the trials showed, with no usage or sourcing recommendations.
What is retatrutide?
Retatrutide (development name LY3437943) is a synthetic peptide in the incretin-mimetic group. Its distinguishing feature: it engages three signaling pathways involved in appetite and metabolism at once. This is why it is often called a triple agonist.
What the trials showed
In clinical trials, the weight findings stood out most: participants achieved, on average, some of the largest reductions reported for this class of drug. Researchers also observed effects on appetite and blood-sugar control, which is why retatrutide is being studied in both obesity and type 2 diabetes.
These results come from early-to-mid trial phases. Large, definitive approval trials are ongoing or being evaluated, and final conclusions about long-term efficacy and safety are still pending.
Retatrutide vs. semaglutide & tirzepatide
- Semaglutide: engages one receptor (GLP-1).
- Tirzepatide: engages two receptors (GIP + GLP-1).
- Retatrutide: engages three receptors (GIP + GLP-1 + glucagon).
The additional glucagon pathway is the main difference from the already-approved drugs semaglutide and tirzepatide.
Approval status
As of now, retatrutide is not approved as a medicine. It is in clinical testing. While semaglutide and tirzepatide are already available as prescription medicines, retatrutide is not yet regularly available.
Frequently asked questions
Is retatrutide approved yet?+
No. Retatrutide is still in clinical testing and not approved as a medicine.
How does it differ from tirzepatide?+
Tirzepatide acts on two receptors (GIP and GLP-1); retatrutide on three (adding glucagon). In trials, retatrutide showed especially large average weight reductions.
Why is retatrutide called a triple agonist?+
Because it simultaneously activates three receptor systems: GIP, GLP-1 and the glucagon receptor.
Related peptides
This site is intended for factual information only. It is not medical advice. This site sells no substances and names no sources.